Streetbeat News

Products Services

BMY

The Phase 3 Checkmate -77T trial of Neoadjuvant Opdivo with chemotherapy followed by surgery and adjuvant Opdivo showed a 42% reduction in the risk of disease recurrence, progression or death in patients with resectable non-small cell lung cancer. The data from the trial will be presented at the European Society for Medical Oncology Congress 2023.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 7:27 pm

AAPL

MSFT

The article discusses how to use an iPad as a second monitor with Apple Inc.'s (NASDAQ:AAPL) or Microsoft Corp.'s (NASDAQ:MSFT) Windows computers. It mentions built-in tools from Apple and third-party apps that can facilitate this. The article also provides a step-by-step guide on how to use Apple's Sidecar feature and third-party apps like Duet Display and Splashtop Wired XDisplay.

Portfolio Pulse from Rounak Jain

October 17, 2023 | 7:22 pm

MBOT

Microbot Medical announced successful initial outcomes of using its LIBERTY Robotic Surgical System in a pre-clinical study, leading to a rise in its share prices.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 7:16 pm

VRTX

Health Canada has granted market authorization for TRIKAFTA, a drug for children aged 2 to 5 years with at least one F508del mutation in cystic fibrosis. The drug is produced by Vertex Pharmaceuticals (VRTX).

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 6:53 pm

BLUE

CRSP

Cantor Fitzgerald initiated coverage on Bluebird Bio Inc (BLUE), expressing cautious optimism for its sickle cell disorder (SCD) therapy, lovo-cel. The analyst noted that while lovo-cel serves a larger market than Bluebird's other therapies, the company's financial outlook is uncertain due to its sizeable expense infrastructure and limited cash runway. The analyst also mentioned that Vertex Pharmaceuticals Inc/CRISPR Therapeutics AG's (CRSP) sickle cell candidate exa-cel is likely to emerge as the leading cell therapy for SCD due to Vertex's significant resource commitment.

Portfolio Pulse from Vandana Singh

October 17, 2023 | 6:40 pm

ASNS

Actelis Networks has received its first order to provide IoT networking to a European natural gas systems operator. This has led to a rise in the company's share prices.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 6:38 pm

CRSP

VRTX

Cantor Fitzgerald has downgraded CRISPR Therapeutics AG (CRSP) to Neutral from Overweight, citing potential barriers and lower than consensus sales estimates for its sickle cell therapy, exa-cel, developed in partnership with Vertex Pharmaceuticals Inc (VRTX). Despite this, the analyst expects a positive recommendation for exa-cel due to its favorable benefit-risk profile. CRSP's stock performance is expected to be closely tied to its product lineup as gene editing technology becomes more common.

Portfolio Pulse from Vandana Singh

October 17, 2023 | 6:33 pm

BMWYY

TSLA

BMW of North America has expanded its electric vehicle charging options for customers in the U.S. and Canada by providing access to Tesla's Supercharger network.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 6:27 pm

GM

General Motors Co (NYSE:GM) plans to delay the production of electric pickup trucks at its Orion, Michigan, facility by a year to late 2025. The decision is aimed at aligning with the changing demand for electric vehicles. GM shares are trading higher by 0.91% at $30.33.

Portfolio Pulse from Shivani Kumaresan

October 17, 2023 | 5:46 pm

HMC

SONY

Sony Group and Honda Motor have unveiled a prototype for the Afeela electric vehicle, which is designed to allow drivers and passengers to download music, maps, and apps through an onboard display. The vehicle is in the final stages of development, with online orders set to begin in 2025 and deliveries starting in North America in spring 2026, followed by Japan later that year.

Portfolio Pulse from Benzinga Newsdesk

October 17, 2023 | 5:40 pm